Special Drug Use Surveillance of LIXIANA Tablet- Long-term use in patients with venous thromboembolism
Phase 4
- Conditions
- Treatment and recurrence prevention of venous thromboembolism [VTE] (deep vein thrombosis [DVT] and pulmonary thromboembolism [PTE])
- Registration Number
- JPRN-UMIN000016387
- Lead Sponsor
- DAIICHI SANKYO COMPANY, LIMITED
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open public recruiting
- Sex
- All
- Target Recruitment
- 1500
Inclusion Criteria
Patients who meet the following requirements when starting to receive LIXIANA (at the time of enrollment for [3]) will be considered for admission to the study:
[1] Patients who have just started to receive LIXIANA for the first time for the treatment and secondary (recurrence) prevention of VTE (DVT and PTE)
[2] Patients who are to start treatment with LIXIANA during the period of contract (as per the signed contract between the institution and the sponsor) and during the enrollment period
[3] Patients who have given written informed consent to the study
Exclusion Criteria
None
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method